JMP Securities analyst Jonathan Wolleben lowered the firm’s price target on Crinetics to $42 from $43 and keeps an Outperform rating on the shares. The firm believes paltusotine will hit in the Phase 3 PATHFNDR-1 trial, setting up the once-daily oral drug to disrupt the acromegaly treatment landscape, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRNX:
- CRNX Upcoming Earnings Report: What to Expect?
- Crinetics to hold a KOL webinar
- Crinetics reports Q2 EPS (94c), consensus (86c)
- Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly